Investing.com30d agobullish
BofA upgrades Moderna after 177% rally driven by cancer vaccine breakthroughInvesting.com -- Bank of America upgraded Moderna to Neutral with a $170 price objective, following a sharp rally in the stock after positive data on its personalized cancer vaccine, intismeran, in adjuvant melanoma.